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Abstract. Dermcidin is a candidate oncogene capable of 
increasing the number of cultured neuronal, breast cancer and 
prostate cancer cells and improving the survival of hepatic 
cells. The dermcidin gene encodes the proteolysis-inducing 
factor core peptide (PIF-CP) and the skin antimicrobial peptide 
DCD-1. The peptide responsible for inducing proliferation 
of cells and the mechanisms involved are unknown. In this 
study, we confirmed a proliferative effect of dermcidin over-
expression of 20% (p<0.02) in the HuH7 human hepatic cell 
line. Proliferation was abrogated by prevention of PIF-CP 
translation or inactivation of its calcineurin-like phosphatase 
domain by site-directed mutagenesis. Prevention of DCD-1 
translation had no effect. Treatment of cells with a 30 amino 
acid synthetic PIF-CP induced an analogous increase in 
proliferation of 14%. Microarray analysis of PIF-CP-treated 
cells revealed low but significant changes in 111 potential 
mediator genes. Pathway analysis revealed several gene 
networks involved in the cellular response to the peptide, one 
with VEGFB as a hub and two other networks converging on 
FOS and MYC. Quantitative PCR confirmed direct upregula-
tion of VEGFB. These data reveal PIF-CP as the key mediator 
of dermcidin-induced proliferation and demonstrate induction 
of key oncogenic pathways.
Introduction
The first evidence of dermcidin (DCD)-induced cell prolifera-
tion arose from studies of the effect of over-expression of the 
identical gene, DSEP, in neural cells (1). DSEP was found to 
decrease the ability of all-trans-retinoic acid to slow cell prolif-
eration and at 3 days post-treatment almost three times more 
DSEP-overexpressing cells than sham-transfected cells were 
present. More recently, Porter et al demonstrated increased 
numbers of 21NT breast cancer cells after stable transfection 
with DCD following 5 and 7 days of cell culture compared to 
cells transfected with empty vector (2). Work from our group 
showed similar results using DCD-transfected prostate 
cancer cells (PC-3M) (3). Additionally, significantly more 
DCD-transfected PC-3M cells stained with Ki-67 compared 
with those transfected with the empty vector. Differential 
DCD expression has also recently been demonstrated in 
human pancreatic, bile duct and gastro-esophageal carci-
noma but not in benign tissue (4). These studies suggest that 
DCD-induced proliferation could have important effects on 
human carcinogenesis and tumour progression.
The DCD gene produces a 110-amino acid polypeptide 
consisting of a 19 amino acid signal peptide, the 30 amino acid 
proteolysis inducing factor-core peptide (PIF-CP), a 13 amino 
acid propetide and the 47 amino acid DCD-1 peptide. The 
peptide responsible for the proliferative effects of DCD has 
yet to be confirmed. At least 2 of the peptides are biologically 
active; firstly the core peptide of proteolysis-inducing factor 
(PIF-CP) (3,4), which is identical to the neuronal survival 
factor Y-P30 (5) and when glycosylated forms the cachectic 
factor described by Todorov et al (6); and secondly DCD-1, 
which has antibiotic activity (7). Structural analysis of PIF-CP 
has demonstrated cleavage of a signal peptide and targeting to 
the secretory pathway (8). This predicts an extracellular action 
consistent with the putative role of DCD as a growth factor 
and oncogene (2). In addition, the central sequence of the 
PIF-CP has homology with the phosphatase domain of calci-
neurin, and appears to be involved in the pro-survival effects 
of dermcidin expression (5,8). However, although calcineurin 
has been suggested to be involved in T-cell activation (9), it 
may inhibit proliferation in neoplastic cells via cdk-4 dephos-
phorylation (10) and has been targeted in anti-proliferative 
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strategies (11). PIF-CP/Y-P30 also binds to calreticulin, which 
induces keratinocyte proliferation (12,13). The target receptor 
for DCD-1 is not known but low-affinity and high-affinity 
DCD receptors on breast cancer cells and a recently described 
PIF receptor on skeletal muscle have been identified (9,14). 
Whether these receptors mediate proliferation and what their 
peptide ligands are remains unknown.
Dermcidin induces multiple changes in gene expres-
sion which have the potential to induce cell proliferation. 
Glycosylated PIF has been demonstrated to induce activation 
of NF-κβ and STAT3 transcription pathways in hepatic cells 
(15), in some endothelial subtypes (16) and in monocytes 
and Kupffer cells (17). Both NF-κβ and STAT3 are known 
to induce proliferation in a variety of cell types including 
pancreatic carcinoma and hepatic cells (18-23). Glycosylated 
PIF has also been shown to increase IL-6 and IL-8 expres-
sion in hepatic and endothelial cells, in which these cytokines 
induce proliferation (15,16,24,25). DCD overexpression results 
in an attenuated response of neuronal cells to treatment 
with all-trans retinoic acid, a differentiating agent with anti-
proliferative transcriptional effects which also interacts with 
calreticulin (26,27).
The aim of this study was to investigate DCD-stimulated 
proliferation in the hepatic carcinoma cell line HuH7. HuH7 
cells do not express DCD endogenously but respond to 
overexpression with an improved survival under conditions 
of oxidative stress (8). We further sought to determine the 
peptide subunit of the DCD polypeptide responsible for prolif-
eration and to investigate the alterations in gene expression 
associated with the proliferative response.
Materials and methods
Polymerase chain reaction (PCR), cloning, site-directed 
mutagenesis and transfection were performed as previously 
described (8) and are detailed in brief below.
PCR. PCR of vector DNA and cellular cDNA was performed 
using primers to the full length native dermcidin cDNA 
(TAGN, Newcastle, UK). Forward primer: CTCGGATCCGC 
CGCCATGAGGTTCATGACTCTCC; reverse primer, CAGA 
ATTCCTGGGTATCATTTCTCAGCT. Twenty-five µl reac-
tion mixtures containing 0.75 µl 25 mM MgCl2, 2.5 µl taq 
poly 10X buffer, 2.5 µl dNTPs, 1 mM forward and reverse 
primers and 1 µl taq polymerase at a 1 in 5 dilution were 
made up in nuclease-free water (all from Promega, Poole, 
UK). A standard cycle of 95˚C for 5 min followed by 35 cycles 
of 95˚C for 1 min, 56˚C for 1 min and 72˚C for 1 min then 
10 min at 72˚C was used. Samples were run on 1.4% agarose 
gels, stained with ethidium bromide and visualised under UV 
illumination.
Site-directed mutagenesis. Site-directed mutagenesis of the 
pcDNA3.1+dermcidin vector was performed using a Quikchange 
II kit (Stratagene, Amsterdam, The Netherlands) according to 
the manufacturer's instructions. Primers used were: N32Q 
forward-CCAGGATCGGGGCAGCCTTGCCATGAAGC; 
reverse-GCTTCATGGCAAGGCTGCCCCGATCCTGG. 
N44Q forward-CAGCAGCTCAAAAGGAACAGGCAGGT
GAAGACCCAG; reverse-CTGGGTCTTCACCTGCCTGTT
CCTTTTGAGCTGCTG. ProP STOP forward-TGCAGGTG
AAGACCCATAGTTAGCCAGACAGGCAC; reverse-GTGC
CTGTCTGGCTAACTATGGGTCTTCACCTGCA. Y-P30 
STOP forward-CTGGTCTGTGCCTAGGATCCAGAGGCC; 
reverse-GGCCTCTGGATCCTAGGCACAGACCAG. H35N 
forward-CGGGGAACCCTTGCAATGAAGCATCAGCAGC; 
reverse-GCTGCTGATGCTTCATTGCAAGGGTTCCCCG. 
Double N32Q, N44Q mutants were created by mutation of the 
pcDNA3.1+dermcidin N32Q plasmid with N44Q primers.
Cloning. Vectors were transformed into TOP10 Eschericia coli 
(Invitrogen, Paisley, UK) as per the manufacturer's instructions 
and plated on LB agar plus 50 µg/ml ampicillin (Sigma, Poole, 
UK). Colonies were screened for insert incorporation by PCR 
and incubated in 3 ml LB+50 µg/ml ampicillin minibroths 
overnight at 37˚C with agitation. Plasmids were prepared by 
alkaline lysis and ethanol precipitation. All plasmids were 
sequenced prior to large scale culture and purification using 
an Endofree plasmid maxi kit (Qiagen, Crawley, UK).
Transfection and cell culture. Plasmids were transfected 
into the HuH7 cell line (European Collection of Cell 
Cultures, UK) using Fugene (Roche Applied Science, Lewes, 
UK) according to the manufacturer's instructions. Stable 
transfectants were selected by culture in 600 µg/ml G418 
(Sigma). Cells were maintained at 37˚C in a 5% CO2 in air 
atmosphere in Dulbecco's modified Eagle's medium with 
10% FCS, 50 U/ ml penicillin, 50 µg/ml streptomycin and 
2 mmol glutamine (Gibco-BRL, Paisley, UK). Transfection 
was confirmed by PCR and Western blotting for DCD and 
neomycin phospho transferase.
Synthetic PIF peptide. A synthesised, >95% purity, full length 
PIF-CP/Y-P30 peptide of 30 amino acids, YDPEAASAP 
GSGNPCHEASAAQKENAGEDP, was purchased from 
Albachem (Gladsmuir, UK). The peptide was added to cell 
cultures at a range of concentrations and cells were incubated 
under standard conditions for 24 hours prior to BrDU immuno-
cytochemistry or RNA extraction.
RNA preparation and reverse transcription. For RNA extrac-
tion cells were seeded at 1x106 per well in 6-well plates and 
incubated overnight under standard conditions. RNA was 
extracted using Trizol (Life Technologies, Paisley, UK) 
according to the manufacturer's instructions. Samples were 
DNAse treated using RQ1 DNAse (Promega) according 
to the manufacturer's instructions. Reverse transcription 
was performed in 20 µl reactions containing 10 µl of RNA 
sample plus 10 µl of RT mix (4 µl 25 mM MgCl2, 2 µl reverse 
transcription 10X buffer, 2 µl dNTP mixture, 1 µl oligo(dT)15 
primer, 0.5 µl AMV reverse transcriptase and 0.5 µl recom-
binant RNasin ribonuclease inhibitor, Promega). Samples 
were then incubated in a thermal cycler (PHC-3, Techne, 
Stone, UK) for 1 h at 42˚C followed by 5 min at 99˚C.
Protein preparation and quantification. Protein lysates were 
prepared using radio-immunoprecipitation assay (RIPA) 
buffer (1X PBS, 1% Nonidet P-40 (BDH Chemicals, Poole, 
UK), 0.5% sodium deoxycholate and 0.1% SDS). One protease 
inhibitor tablet (Roche) was added to each 10 ml of RIPA 
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prior to use. Culture medium was removed and cells washed 
with sterile PBS. RIPA buffer (500 µl) was then added to 
each well and cells lysed by scraping and passaging through 
a 21G needle. Lysates were placed in microcentrifuge tubes 
and centrifuged at 10,000 g for 10 min at 4˚C. The resultant 
protein supernatant was transferred to a fresh microcentrifuge 
tube for protein assay. Protein concentrations were deter-
mined using a Bio-Rad DC protein assay kit according to the 
manufacturer's instructions.
Western blotting. Western blot analyses were performed using 
12.5% Bis-Tris gels (Bio-Rad, Hemel Hempstead, UK) and a 
Bio-Rad Miniprotean II system. Wells were loaded with 10 µg 
of protein pre-incubated with LSB. Gels were run at 100 V for 
~1 h and transferred to nitrocellulose membranes (Bio-Rad) 
by semi-dry blotting at 100 V for 1 h. Membranes were incu-
bated for 1 h at room temperature with mouse anti-neomycin 
phosphotransferase primary antibody (Upstate, Watford, UK) 
at 1 µg/ml in 5% Marvel in tris-buffered saline. They were 
then washed for 5 min 3 times in 0.05% Tween (Sigma) in 
TBS and incubated for 1 h at room temperature with goat 
anti-mouse peroxidise-linked secondary antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) at 1 in 100 in 5% 
Marvel in tris-buffered saline. Following a further 3 washes 
chemiluminescence was performed using the Amersham ECL 
system (Amersham Biosciences Ltd., Buckinghamshire, UK).
Bromodeoxyuridine labelling and immunocytochemistry. For 
immunocytochemical analysis HuH7 cells were seeded at 
10,000 cells per well in 8-well chambered slides (Nunc, VWR 
International, Poole, UK) and cultured overnight under stan-
dard conditions. In experiments in which the synthetic PIF 
peptide was used, this was added at the desired concentration 
and cells cultured for a further 24 h. Cells were then labelled 
by incubation for 1 h with 1 in 1000 bromodeoxyuridine 
(BrDU, Cell Proliferation Labelling Reagent, Amersham, 
Chalfont St Giles, UK). Culture chambers were removed and 
slides washed in PBS prior to overnight fixation at 4˚C in 
80% ethanol. Slides were then washed in PBS for 10 min and 
incubated in 5 M HCl for 45 min at room temperature. Two 
further 5-min PBS washes were performed and the chambers 
on the slides were demarcated using a greasepen. Slides 
were blocked by incubation in 50 µl per well of 20% normal 
goat serum (DakoCytomation, Ely, UK) in PBS plus 0.05% 
Tween-20 for 10 min at room temperature. Slides were then 
incubated for 1 h at room temperature with 50 µl per well of 
monoclonal rat anti-BrDU antibody (Oxford Biotechnology, 
Kidlington, UK) at 1 in 100 in blocking solution and washed 
3 times in PBS. Slides were incubated for 30 min at room 
temperature with 50 µl per well of goat anti-rat peroxidase-
linked secondary antibody (Santa Cruz Biotechnology) at 1 in 
300 in blocking solution and washed again 3 times with PBS.
Slides were stained using a liquid DAB + substrate-
chromogen system (Dako) according to the manufacturer's 
instructions and counterstained with haematoxylin. A light 
microscope and graticule were used to count at least 500 
nuclei per chamber.
Microarray hybridisation and data analysis. For use in micro-
array experiments 1x106 HuH7 cells per well were seeded in 
6-well plates and incubated overnight prior to incubation with 
10 ng/ml of synthetic PIF peptide for 24 h. The experiment 
was performed in sextuplicate. Total RNA was extracted and 
subjected to a modification of the Agilent low RNA input 
Fluorescent linear amplification protocol (Agilent, South 
Queensferry, UK). The manufacturer's protocol was followed 
with the exception of using 1.2 µl of Cy3- or Cy5-labeled 
CTP (10 mM) during the cRNA synthesis step. Arrays used 
were Human cDNA Clone Set Array Version 2 arrays (MRC 
HGMP-RC, Cambridge, UK).
Microarray hybridisation and washing was performed 
according to the Agilent protocol following a reciprocal 
sample labelling and hybridisation dye-swap scheme. The 6 
synthetic PIF peptide-treated samples were co-hybridised with 
the 6 control samples, with one dye-swap array for each of 
these, bringing the total number of arrays to 12, hybridised 
with 24 samples. Slides were scanned using the Agilent 2505B 
microarray scanner and images analysed using Agilent feature 
extraction software. Data were analysed using R/Bioconductor 
and in particular the limma package (28) for steps consisting 
of background noise correction, normalisation and testing of 
statistical hypotheses. Briefly, measured background noise 
in the raw data was subtracted from the measured signal for 
each probe. For purposes of normalisation, an assumption of 
global similarity between samples and arrays was made as 
only a small proportion of probes were expected to change 
between the biological conditions under investigation. Within-
array distribution of log2 scale expression ratios between test 
and control sample was non-linearly centred around 0 by way 
of a locally weighted regression algorithm (LOWESS). The 
normalised expression ratios where then made comparable 
across arrays by matching the per-array distributions to one 
another, using median absolute deviation estimates for this 
scaling. A statistical null hypothesis of ‘no difference in 
mean expression between PIF and control’ was then tested 
for each gene, using a linear model with an empirical Bayes 
moderated t-statistic (moderated by variance information 
borrowed from multiple genes). Due to the presence of dye 
swap arrays, dye effect was also accounted for in this model. 
For the purposes of this analysis, genes with an estimate of 
statistical significance of p≤0.05 and a differential expression 
cut-off of 1.25-fold up or down-regulation. A multiple testing 
correction of p-values was not applied, given that the purpose 
of the microarray analysis here is to provide a sorted list 
of statistically relevant genes for further follow-up. A pro-
portion of false-positive results was considered acceptable 
due to use of other validation techniques. Microarray data 
have been deposited in the GPX MIAME compliant database 
at http://gpx.gti.ed.ac.uk/ (accession no. GPX-00080.1 will 
be made available upon publication).
Network analysis was performed after upload of a gene list 
of 111 differentially expressed genes as input for the Ingenuity 
Pathways Analysis software application (Ingenuity® Systems, 
Redwood City, CA). The IPA Knowledge Base, a comprehen-
sive manually curated database of biological interactions for 
human, mouse and rat genes was used to construct pathways 
and networks. IPA maps each gene identifier in the uploaded 
dataset (focus genes) to its corresponding object in the IPA 
Knowledge Base and overlays these onto a global molecular 
network developed from the Knowledge Base. Networks of 
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focus genes were then algorithmically generated based on 
connectivity and assigned a significance score representing 
the statistical likelihood of chance occurrence. A high number 
of focus genes within a network leads to a higher network 
score (negative exponent of respective p-value). For functional 
analysis, differentially regulated genes associated with biolog-
ical functions and/or diseases in the Ingenuity Knowledge 
Base were analysed using a Fisher's exact test to calculate a 
p-value determining the probability that each biological func-
tion and/or disease assigned to that data set is due to chance 
alone. For canonical pathways analysis, genes associated with 
a canonical pathway in the Ingenuity Knowledge Base were 
analysed in 2 ways: i) a ratio of the number of genes from the 
data set that map to the pathway divided by the total number 
of genes that map to the canonical pathway was calculated; 
ii) Fisher's exact test was used to calculate a p-value deter-
mining the probability that the association between the genes 
in the dataset and the canonical pathway is explained by 
chance alone.
Real-time PCR. Real-time PCR for VEGF-B was performed 
using an ABI 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Warrington, UK) according to the manufacturer's 
instructions. The 18S rRNA gene was used as an endogenous 
control to normalize for differences in the amount of total 
RNA in each sample. Eukaryotic 18S rRNA endogenous 
control (VIC/TAMRA probe, primer limited) and VEGF-B 
TaqMan Gene Expression Assays (assay id Hs00173634_m1) 
were purchased from Applied Biosystems.
Real-time PCR reactions (10 µl) were set up consisting 
of 5 µl TaqMan Universal PCR Master Mix (Applied 
Biosystems), 0.5 µl TaqMan Gene Expression Assays and 
4.5 µl sample cDNA. Each PCR reaction contained 6.5 ng 
of reverse transcribed RNA in 10 µl. All samples were run 
in triplicate in a 384-well real-time PCR plate (Applied 
Biosystems). Wells were heat-sealed with plastic film. The 
plate was centrifuged at 4000 g for 1 min then inserted into 
the ABI 7900HT. Conditions for the PCR reaction were 2 min 
at 50˚C, 15 min at 95˚C and then 40 cycles, each consisting 
of 15 secs at 95˚C, and 1 min at 60˚C. Cycle-cycle changes 
in fluorescence in each sample were measured and a kinetic 
profile of amplification over the 40-cycle PCR reaction was 
generated. Only samples with an 18S CT value of <23 were 
assumed to contain RNA of sufficient quality for analysis of 
VEGF-B expression. To determine the relative RNA levels 
within the samples, standard curves for the PCR reaction were 
prepared by using the cDNA from one sample and making 
2-fold serial dilutions covering the range equivalent to 39.2-
1.6 ng of RNA. The relative standard curve method was used 
to determine the fold change in VEGF-B expression in treated 
and untreated cells.
Statistical analysis. Experiments were performed in triplicate 
with the exception of microarray experiments which were 
performed in sextuplicate. In bromodeoxyuridine experiments 
the coefficient of variation over the range measured was 11% 
in experiments using transfected cells and 7% in experiments 
using untransfected cells. Data were analysed using the 
Student's t-test and p<0.05 were considered significant.
Results
Creation of dermcidin mutants. Site-directed mutagenesis 
was used to alter the codons within the native DCD cDNA 
in the pcDNA3.1+mammalian expression vector. The poten-
tially-glycosylated asparagine residues of the calcineurin-like 
phosphatase domain were removed by substituting gluta-
mine for asparagine in the N32Q, N44Q and N32Q N44Q 
mutants. A further mutation to eliminate the most highly 
conserved residue of this domain was also designed, which 
converted the histidine residue at position 35 to asparagine. 
This mutation has been demonstrated previously to prevent 
phosphatase activity in calcineurin (29). Additionally, two 
truncation mutants were generated by inserting STOP codons 
immediately 5' to the propeptide sequence (which is 5' to the 
DCD-1 sequence) in the ProP STOP vector and immediately 
5' to the Y-P30 sequence in the Y-P30 STOP vector. Due to 
a high A and T content it was not possible to design primers 
to introduce a STOP codon immediately prior to the DCD-1 
sequence which were compatible with the Quikchange muta-
genesis system's annealing temperatures. All mutated plasmid 
sequences were confirmed by direct sequencing.
PCR of cDNA from all transfected cells confirmed expres-
sion (Fig. 1A). A low level of background DCD expression 
developed following prolonged culture (same number of 
passages as transfected cells) of untransfected HuH7 cells as 
previously described (8). The short nature of the translated 
sequences and their predicted low antigenicity rendered the 
generation of antibodies to each mutant peptide unfeasible. 
Anti-neomycin phosphotransferase confirmed that the vectors 
were active only in transfected cells (Fig. 1B). All effects of 
transfection were subsequently controlled for. Assessment of 
protein expression in HuH7 cells transfected with the N32Q, 
N44Q, N32QN44Q vectors has previously been performed in 
the same manner (8).
Figure 1. (A) PCR confirmation of dermcidin transfection in HuH7 cells. 
The expected PCR product of the full length native cDNA is 387 bp. Lane 1, 
untransfected HuH7 cell cDNA, early passage. Lane 2, untransfected HuH7 
cDNA, prolonged passage. Lane 3, empty pcDNA3.1+transfected HuH7 
cDNA. Lane 4, pcDNA3.1+dermcidin transfected HuH7 cDNA. Lane 5, 
pcDNA3.1+ProP STOP transfected HuH7 cDNA. Lane 6, pcDNA3.1+Y-P30 
STOP transfected HuH7 cDNA. Lane 7, pcDNA3.1+H35N transfected HuH7 
cDNA. (B) Anti-neomycin phsophtransferase Western blotting to assess 
HuH7 cell transfection. The molecular mass of neomycin phosphotrans-
ferase is 30 kDa. Lane 1, empty vector transfected HuH7 cell lysate. Lane 2, 
pcDNA3.1+dermcidin transfected HuH7 cell lysate. Lane 3, pcDNA3.1+ProP 
STOP transfected HuH7 cell lysate. Lane 4, pcDNA3.1+Y-P30 STOP trans-
fected HuH7 cell lysate. Lane 5, pcDNA3.1+H35N transfected HuH7 cell 
lysate. Lane 6, untransfected HuH7 cell lysate.
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Assessment of cell proliferation in transfected HuH7 cells. 
BrDU immunocytochemistry of DCD-transfected HuH7 
cells resulted in clearly distinguishable positive and nega-
tive nuclear staining (Fig. 2A). The proportion of positively 
staining sham-transfected cells was 29%. Stable transfection 
of the native DCD-containing vector pcDNA3.1+dermcidin 
resulted in a 20% increase in cells positive for BrDU in 
comparison with transfection with the empty vector (Fig. 2B) 
(Student's t-test, p<0.02). Transfection of the ProP STOP and 
N32Q mutants resulted in similar significant increases in 
cell proliferation of 23% (Student's t-test, p<0.02 and p<0.05 
respectively). A lower, non-significant increase in prolifera-
tion of 15% was seen in the N44Q mutant. The Y-P30 STOP, 
N32QN44Q and H35N mutants resulted in non-significant 
increases in proliferation of 2, 8 and 7% respectively (Fig. 2B).
Induction of cell proliferation by a synthetic PIF-CP peptide. 
HuH7 cells treated with the synthetic PIF-CP peptide showed 
no identifiable changes in cell morphology. Cell counts for 
BrDU positivity revealed that the synthetic peptide increased 
cell proliferation (Fig. 3). The response had a bell-shaped 
dose-response curve and produced a maximum increase of 
14% at a peptide concentration of 10 ng/ml (Student's t-test, 
p<0.05).
Effect of PIF-CP peptide treatment on HuH7 gene expression. 
For microarray analysis, HuH7 cells treated with the synthetic 
PIF peptide were compared with untreated cells. There were 
111 genes with a fold change ≥1.25 and empirical Bayes test 
p≤0.05. For brevity, 51 genes with a fold change ≥1.3 and 
empirical Bayes test p≤0.05 are presented in Table I. To 
further investigate the differential expression observed we 
sought to analyse the networks, functions and pathways in 
which these genes played a role. Pathways analysis of the 
differentially expressed genes using Ingenuity Pathways 
Analysis (Ingenuity Systems) revealed 4 networks of high 
connectivity containing a high number of PIF peptide-regu-
lated genes. Network 3 (network score of 23 and 14/35 focus 
molecules) centred on FOS, LIF, VEGF, ERBB2 and HRAS, 
of which VEGFB was directly regulated by the PIF-CP 
peptide. Upregulation of VEGFB expression was confirmed 
by real-time PCR which demonstrated a mean increase in 
expression similar to that of microarray experiments of 
1.89-fold. Network 1 (network score of 25 and 15/35 focus 
molecules) centred on TNF, TGFβ1 and IL-4, although 
none of these genes were directly regulated by the PIF-CP 
peptide. Network 2 (network score of 23 and 14/35 focus 
molecules) centred on TP5 3, THRB and MYOD1, none 
of which were directly regulated by the PIF-CP peptide. 
Network 4 (network score of 18 and 12/35 focus molecules) 
centred on HGF and MYC, neither of which were directly 
regulated by the PIF peptide.
Analysis of the functional groupings of the most variable 
1500 genes revealed the most significant changes in expres-
sion of genes involved in cardiovascular system development 
and function, cell morphology, skeletal and muscular system 
development and function, cancer, cell death and the cell cycle 
(Fig. 4A).
Figure 2. Transfected HuH7 cell proliferation assay. (A) Representative 
immunocytochemical appearance. (B) Effect of different pcDNA3.1+vector 
inserts on the proportion of transfected HuH7 cells staining for BrDU. Cells 
(1x105) per well were seeded in 8-well slide chambers and cultured for 
24 h. Staining was then performed with a rat anti-BrDU primary antibody 
and goat anti-rat peroxidase-linked secondary antibody. Slides were stained 
with a liquid DAB+substrate chromogen system and haematoxylin counter-
staining. Positive and negative nuclei were counted using a graticule. HuH7 
cells transfected with the native DCD cDNA, the ProP STOP mutant and 
the N32Q mutant showed a significant increase in cell proliferation in com-
parison with empty vector-transfected cells. This increase was effectively 
abrogated by the Y-P30 STOP and H35N STOP mutations. The N44Q and 
N32QN44Q mutations had lesser effects. *p<0.05. **p<0.02 (t-test).
Figure 3. Effect of treatment of HuH7 cells with a synthetic peptide cor-
responding to the PIF-core peptide. Cells were seeded at 10,000 cells per 
well in 8-well chambered slides and cultured overnight under standard con-
ditions. They were then cultured for 24 h in standard medium containing 
a range of concentrations of synthetic PIF-core peptide. A dose-dependent 
increase in cells staining positive for BrDU was observed which peaked at a 
peptide concentration of 10 ng/ml. *p<0.05 (t-test). 
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Analysis of the involvement of differentially regulated 
genes in known canonical pathways revealed most significant 
involvement in nitric oxide signalling in the cardiovascular 
system, ubiquinone synthesis and death receptor signalling 
(Fig. 4B). Although many other pathways were implicated they 
did not reach the threshold of significance (values expressed 
as -log of p-value with threshold of 1.30 representing -log of 
0.05).
Discussion
The results of this study demonstrate that dermcidin expres-
sion induces HuH7 cell proliferation. In DCD overexpression 
experiments the proportional increase in proliferating cells 
was 20%. Stimulation with the synthetic PIF-core peptide 
resulted in an increase in proliferation of 14%. These findings 
were both significant and are consistent with previous studies 
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Figure 4. Functional analysis of differentially regulated genes. Functional 
grouping. Differentially regulated genes associated with biological functions 
and/or diseases in the Ingenuity Pathways Knowledge Base were analysed 
using a Fisher's exact test to calculate a p-value determining the probability 
that each biological function and/or disease assigned to that data set is 
due to chance alone. Threshold of 1.30 is the negative log of p=0.05. CVS, 
cardiovascular. MSK, musculoskeletal. (B) Involvement of PIF core peptide-
regulated genes in canonical pathways. Genes associated with a canonical 
pathway in the Ingenuity Pathways Knowledge Base were analysed in 2 
ways: i) a ratio of the number of genes from the data set that map to the 
pathway divided by the total number of genes that map to the canonical 
pathway was calculated; ii) Fisher's exact test was used to calculate a p-value 
determining the probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance alone. Threshold 
of 1.30 is the negative log of p=0.05. CVS, cardiovascular. 
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on the proliferative effects of DSEP/dermcidin expression 
(1-3). The increased proportion of cells entering S-phase 
demonstrated by BrDU staining suggests cell cycling rather 
than decreased cell death secondary to the pro-survival 
effects of DCD expression (8).
When translation of the sequence 3' to Y-P30 including 
the propeptide and DCD-1 coding areas (ProP STOP mutant) 
was prevented there was little effect on dermcidin-induced 
proliferation suggesting these peptides are not crucial for this 
effect. In contrast, when translation of the Y-P30 sequence 
was prevented the proliferative effect of overexpression was 
abrogated. This suggests that the Y-P30/PIF-core peptide 
is responsible for the proliferative effects of dermcidin. 
Experiments using the synthetic PIF-core peptide support 
this conclusion in that proliferation of a similar magnitude 
was observed. The bell-shaped dose-response curve following 
Huh7 treatment with synthetic PIF-CP is characteristic of 
biological responses to several cytokines and growth factors 
including IFN-γ, IL-6, IL-8 and TNF-α (30-33). It has also 
been suggested that bell-shaped dose-response curves may 
result from the action of an agonist on two separate recep-
tors (34). It is therefore intriguing to hypothesise that HuH7 
cells may express both the high- and low-affinity receptors 
previously reported (2,35), and that these receptors may have 
differential effects on proliferation.
The finding that dermcidin-induced cell proliferation is 
prevented by the N32QN44Q and H35N mutations further 
supports the role of the PIF-CP in the induction of prolifera-
tion, as both of these mutations lie within the PIF-CP amino 
acid sequence. Furthermore, these mutations lie within the 
calcineurin phosphatase-like domain (5). An effect of calci-
neurin signalling on cell proliferation has previously been 
demonstrated in pancreatic cancer cells and interestingly 
this effect was mediated by myc, which we found to be a 
key mediator in network 4 (36). Histidine is the most highly 
conserved amino acid across the calcineurin-like family of 
phosphatases (37) and its removal has been demonstrated 
to cause a significant decrease in enzyme activity (29,38). 
It is therefore feasible that the replacement of histidine with 
asparagine in the H35N mutant reduces Y-P30 phosphatase 
activity. The reason for the lack of proliferative effect of 
the N32QN44Q mutant is less clear. This mutation does not 
appear to affect N-glycosylation in HuH7 cells (8) and the 
single mutations N32Q and N44Q did not affect proliferation. 
In the calcineurin phosphatase domain, the role of aspara-
gine residues has not been investigated, although they are a 
conserved part of the active phosphatase site (37). Mutation 
of both asparagines may therefore disrupt the phosphatase 
site but mutation of either alone appears insufficient to do 
so. One way to test this hypothesis would be to extend the 
studies of para-nitrophenyl phosphate cleavage by Y-P30 
performed by Cunningham et al (5). In particular, synthesis 
of peptides containing the H35N and N32QN44Q mutations 
and comparison of their proliferative effects with those of the 
native peptide would help elucidate the role of these amino 
acids in DCD/PIF-CP induced proliferation.
Microarray analysis showed relatively small fold-changes 
in gene expression mediated by the PIF-core peptide. This 
may, in part, reflect the experimental and analytical methods 
used. The technique of LOWESS normalisation used to correct 
for dye bias assumes that this bias is dependent on spot 
intensity with the subsequent effect of smoothing all signals. 
Similarly, the use of reciprocal Cy3/Cy5 labelling for sample 
and control specimens would be expected to lessen overall 
fold-changes. Nevertheless, the fact that synthetic PIF-CP 
treatment had a small effect on the magnitude of gene expres-
sion changes suggests that its effect on proliferation is more 
likely to be mediated through a change in the pattern of 
expression rather than the control of a single ‘switch’ gene. 
Ingenuity Pathways Analysis was performed to examine 
networks of interacting genes differentially expressed after 
PIF treatment. As the microarray platform used in this study 
did not provide full coverage of the human genome differential 
expression data were not available for many of the potential 
interacting partners in networks or canonical pathways. 
Despite this however, Ingenuity Pathways Analysis revealed 
several networks of high connectivity which may mediate the 
proliferative effect of the PIF-CP. In network 1, peptide treat-
ment increased CCNB1 (cyclin B1) expression. As part of the 
cyclin B1-CDK1 complex this would be expected to promote 
progress from G2 to M, contributing to the highly complex 
activation of cyclin B1 (39). In network 2, the IGFBP2 growth 
factor binding protein, previously demonstrated to promote 
Akt-driven transformation (40), was upregulated. However, 
in HuH7 cells IGFBP2 has previously been demonstrated 
to be secreted on growth inhibition by histone deacetylase 
treatment (41). It is not clear if IGFBP2 expression reflects a 
pro-proliferative ‘escape' effect or an anti-proliferative effect 
in this model. In network 3, VEGFB was upregulated. This 
response was validated using real-time PCR. VEGF is known 
to be produced by HuH7 cells and has pro-proliferative in 
addition to its well-characterised angiogenic effects (42-45). 
Network 3 was unusual in converging on a single nuclear 
target, FOS. FOS has been well defined as a pro-proliferative 
oncogene, but in HuH7 cells appears to mediate myc-insti-
gated apoptosis (46,47). Myc is known to function as a pivot, 
determining whether cells undergo apoptosis or growth, and it 
is therefore possible that its status could influence the effect of 
network 3. Interestingly, myc and fos are central in network 4, 
and although not directly regulated by PIF-CP, myc interacts 
with several directly regulated genes. Determining or creating 
changes in the status of fos and myc may cast light on the 
influence of dermcidin-regulated genes on proliferation.
Functional analysis of differentially regulated genes 
suggested their involvement in cardiovascular system devel-
opment and function, cell morphology, skeletal and muscular 
development and function, cancer, cell death, gastrointestinal 
disease and cell cycling. These functions and in particular 
cell cycling are all consistent with the proliferative effect 
observed in HuH7 cells. Similarly, they support the previously 
described functions of dermcidin as an oncogene (2), survival 
peptide (5,8) and cachectic factor (6). These functions have 
also previously been ascribed to the Y-P30/PIF core peptide. 
No anti-microbial function was found and this is consistent 
with the antibiotic action of dermcidin being mediated by 
the DCD-1 peptide rather than the PIF-CP (7). The regula-
tion of genes involved in cardiovascular system development 
and function, cell morphology and gastrointestinal disease 
suggests dermcidin may have previously unrecognised func-
tions in these areas.
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Pathways analysis demonstrated statistically significant 
involvement of PIF-CP-regulated genes in 3 pathways: nitric 
oxide signalling in the cardiovascular system, ubiquinone 
biosynthesis and death receptor signalling. Dermcidin expres-
sion is known to protect cells from oxidative stress (5,8,48) 
and it is feasible that this effect involves part of the nitric 
oxide signalling pathway. However, a functional role in the 
cardiovascular system has not been described. Dermcidin has 
similarly not previously been demonstrated to play a role in 
ubiquinone biosynthesis. Ubiquinone's roles in the respiratory 
chain (49) and in the prevention of ceramide-induced apop-
tosis (50,51) suggest that it may also be a mechanism involved 
in the pro-survival effect of dermcidin (5,8). Ubiquinone is 
involved in the intrinsic pathway of apoptosis. The possibility 
that dermcidin also influences the extrinsic pathway is raised 
by its regulation of genes with functions in death receptor 
signalling. A combination of genes involved in both pathways 
may explain its pro-survival effect.
The finding that dermcidin induces tumour cell prolifera-
tion confirms its oncogenic potential. Autocrine secretion of 
dermcidin would be expected to contribute to the autonomous 
growth of tumour cells. DCD has recently been shown to 
have a differential level of expression across different tumour 
types, with bilio-pancreatic tumours having the greatest levels 
of expression (48). Overexpression has been suggested to 
occur through the amplification of the dermcidin gene locus 
in breast cancer (2). Alternatively, as with other oncogene 
pathways involving secreted products, abnormalities in the 
receptor system or signalling pathways could contribute to 
tumour cell expansion (52). Of the signalling pathways known 
to be stimulated by glycosylated PIF, there is some evidence 
that the proteasome pathway may be involved in the induc-
tion of cell proliferation. In pancreatic cancer, inhibition of 
the 26S proteasome has been found to inhibit proliferation, 
potentially via prevention of p21WAF-1 degradation (53). It is 
feasible that a similar effect in HuH7 cells could contribute to 
the pro-proliferative effects we have observed (54,55).
We have demonstrated that dermcidin has proliferative 
effects in HuH7 cells which are mediated via the Y-P30/
PIF-CP peptides and probably the calcineurin phospha-
tase-like domain. Further studies correlating inhibition of 
dermcidin-regulated genes with its pro-proliferative effects 
will aid in determining the exact mechanisms responsible. We 
have also identified several functions and pathways not previ-
ously known to be regulated by dermcidin. Their study may 
reveal important new biological roles.
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